Compare Novartis AG (NVS) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Williams Companies Inc — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Novartis AG is far larger — about 3× Williams Companies Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Williams Companies Inc for 58 Days on average.
| NVS | WMB | |
|---|---|---|
Market Cap | $268.57B | $88.48B |
Volume | 1,532,573 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $168.62 | $79.40 |
52-Week Low | $121.80 | $56.51 |
Typical Hold Time | 82 Days | 58 Days |
Enterprise Value | $309.89B | $119.11B |
Dividend Yield | 3.31% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Williams Companies (WMB) trades at $71.46, down 1.28% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with 25.18% net income margin and 24.02% ROE, though recent earnings have been mixed with two misses and one beat. Analyst consensus is strongly bullish with 79% buy ratings and an $87.27 price target, representing 22% upside. Recent news highlights WMB's positioning to benefit from AI-driven natural gas demand growth.
WMB offers compelling value with strong cash flow generation and dividend growth potential, though investors face risks from energy market volatility and high debt levels. The company's fee-based revenue model provides stability, while strategic acquisitions like Momentum Midstream enhance growth prospects. Current valuation at 28.82 P/E appears reasonable given the growth trajectory and defensive characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
